In July, Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million. Artiva is a clinical-stage biotechnology company focused on developing cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently in clinical trials for systemic lupus erythematosus, patients with or without lupus nephritis, and an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both ...